These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 17703252

  • 1. Dramatic reduction in tumour size in hepatocellular carcinoma patients on thalidomide therapy.
    Demeria D, Birchall I, Bain VG.
    Can J Gastroenterol; 2007 Aug; 21(8):517-8. PubMed ID: 17703252
    [No Abstract] [Full Text] [Related]

  • 2. Low dose of thalidomide can be effective in advanced hepatocellular carcinoma.
    Chen SC, Tsai HJ, Jan CM, Wang YH, Chen LT.
    J Gastroenterol Hepatol; 2006 Dec; 21(12):1868-9. PubMed ID: 17074035
    [No Abstract] [Full Text] [Related]

  • 3. Hepatocellular carcinoma with intra-atrial tumor thrombi. A report of three cases responsive to thalidomide treatment and literature review.
    Chang JY, Ka WS, Chao TY, Liu TW, Chuang TR, Chen LT.
    Oncology; 2004 Dec; 67(3-4):320-6. PubMed ID: 15557794
    [Abstract] [Full Text] [Related]

  • 4. Effect of thalidomide in hepatocellular carcinoma: assessment with power doppler US and analysis of circulating angiogenic factors.
    Hsu C, Chen CN, Chen LT, Wu CY, Hsieh FJ, Cheng AL.
    Radiology; 2005 May; 235(2):509-16. PubMed ID: 15858091
    [Abstract] [Full Text] [Related]

  • 5. Perfusion computed tomography in patients with hepatocellular carcinoma treated with thalidomide: initial experience.
    Petralia G, Fazio N, Bonello L, D'Andrea G, Radice D, Bellomi M.
    J Comput Assist Tomogr; 2011 May; 35(2):195-201. PubMed ID: 21412089
    [Abstract] [Full Text] [Related]

  • 6. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide.
    Patt YZ, Hassan MM, Lozano RD, Ellis LM, Peterson JA, Waugh KA.
    Am J Clin Oncol; 2000 Jun; 23(3):319-21. PubMed ID: 10857902
    [Abstract] [Full Text] [Related]

  • 7. Sinonasal metastatic hepatocellular carcinoma.
    Huang HH, Chang PH, Fang TJ.
    Am J Otolaryngol; 2007 Jun; 28(4):238-41. PubMed ID: 17606038
    [No Abstract] [Full Text] [Related]

  • 8. Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma.
    Hsu WC, Chan SC, Ting LL, Chung NN, Wang PM, Ying KS, Shin JS, Chao CJ, Lin GD.
    Jpn J Clin Oncol; 2006 Feb; 36(2):93-9. PubMed ID: 16517834
    [Abstract] [Full Text] [Related]

  • 9. Thalidomide for advanced hepatocellular carcinoma: is this a real alternative?
    Wadler S.
    Cancer; 2005 Jan 01; 103(1):1-4. PubMed ID: 15565637
    [No Abstract] [Full Text] [Related]

  • 10. Functional Imaging and Assessment of Antitumor Activity in Systemic Therapy for Hepatocellular Carcinoma.
    Kambadakone A, Baliyan V, Zhu AX.
    Semin Liver Dis; 2017 Aug 01; 37(3):259-274. PubMed ID: 28847036
    [No Abstract] [Full Text] [Related]

  • 11. Antineoplaston treatment for advanced hepatocellular carcinoma.
    Kumabe T, Tsuda H, Uchida M, Ogoh Y, Hayabuchi N, Sata M, Nakashima O, Hara H.
    Oncol Rep; 1998 Aug 01; 5(6):1363-7. PubMed ID: 9769368
    [Abstract] [Full Text] [Related]

  • 12. Percutaneous ethanol injection therapy (PEIT) for hepatocellular carcinoma (HCC).
    Mueller PR.
    Jpn J Cancer Res; 1995 Nov 01; 86(11):inside front cover. PubMed ID: 8567388
    [No Abstract] [Full Text] [Related]

  • 13. Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma.
    Mascarenhas RC, Sanghvi AN, Friedlander L, Geyer SJ, Beasley HS, Van Thiel DH.
    Oncology; 2004 Nov 01; 67(5-6):471-5. PubMed ID: 15714004
    [Abstract] [Full Text] [Related]

  • 14. alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma.
    Chen LT, Liu TW, Chao Y, Shiah HS, Chang JY, Juang SH, Chen SC, Chuang TR, Chin YH, Whang-Peng J.
    Aliment Pharmacol Ther; 2005 Aug 01; 22(3):217-26. PubMed ID: 16091059
    [Abstract] [Full Text] [Related]

  • 15. A fishy nodule.
    Jarry J, Nguyen V, Imperato M.
    Gastroenterology; 2012 Jan 01; 142(1):e26-7. PubMed ID: 22107715
    [No Abstract] [Full Text] [Related]

  • 16. Predictive factors for intrahepatic recurrence after percutaneous ethanol injection therapy for small hepatocellular carcinoma.
    Koda M, Murawaki Y, Mitsuda A, Ohyama K, Horie Y, Suou T, Kawasaki H, Ikawa S.
    Cancer; 2000 Feb 01; 88(3):529-37. PubMed ID: 10649243
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of tumor response to systemic therapy in hepatocellular carcinoma.
    Gafton B, Pârciu S, Murguleţ E, Bălan G.
    Rev Med Chir Soc Med Nat Iasi; 2012 Feb 01; 116(4):1005-10. PubMed ID: 23700879
    [Abstract] [Full Text] [Related]

  • 18. [Significance of lipiodol-CT in the evaluation of therapeutic effects of Lp-TAE for hepatocellular carcinoma--clinicopathologic study].
    Jinno K, Tokuyama K, Yumoto Y, Wada T, Okamoto T, Kobashi H, Moriwaki S, Tanada M, Maeda H, Konno T.
    Nihon Gan Chiryo Gakkai Shi; 1988 Aug 20; 23(8):1660-71. PubMed ID: 2848080
    [No Abstract] [Full Text] [Related]

  • 19. An uncommon pattern of cardiac invasion in hepatocellular carcinomaHCC, hepatocellular carcinoma.
    Anton E, Astiazaran A.
    J Clin Pathol; 2006 Dec 20; 59(12):1337. PubMed ID: 17142579
    [No Abstract] [Full Text] [Related]

  • 20. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
    Gavanier M, Ayav A, Sellal C, Orry X, Claudon M, Bronowicki JP, Laurent V.
    Eur J Radiol; 2016 Jan 20; 85(1):103-112. PubMed ID: 26724654
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.